Results 71 to 80 of about 17,271 (194)

Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

open access: yes, 2022
20.500.12530/87858Spironolactone when combined with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) may theoretically exert androgenic properties, thereby compromising the therapeutic effectiveness of abiraterone. Two patients with
Vicente-Valor, Juan   +19 more
core   +1 more source

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer

open access: yesClinical and Translational Science
Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration‐resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed
Nadine Norton   +12 more
doaj   +1 more source

Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study

open access: yesTherapeutic Advances in Medical Oncology, 2020
Background: Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies.
Giuseppe Procopio   +21 more
doaj   +1 more source

Quantitation of Cirtuvivint (SM08502) in Human Plasma by LC–MS/MS

open access: yesBiomedical Chromatography, Volume 40, Issue 10, October 2026.
ABSTRACT CDC‐like kinases (CLK) and dual‐specificity tyrosine‐regulated kinases (DYRK) are protein kinases involved in various cellular functions, mRNA splicing, and DNA damage repair. CLK/DYRK kinases have been implicated in many disorders such as diabetes, neurodegenerative diseases, and cancer.
Julianne L. Holleran   +10 more
wiley   +1 more source

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer

open access: yes, 2018
BACKGROUND: A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3beta-hydroxysteroid dehydrogenase 1 (3betaHSD1) missense that increases metabolic flux from extragonadal precursor steroids to DHT synthesis in prostate cancer.
Alyamani, Mohammad   +19 more
core   +1 more source

Improved prostate cancer therapeutics through KinetiSol® enabled amorphous solid dispersions of Abiraterone [PDF]

open access: yes, 2019
A majority of anticancer drugs have inherently poor water solubility, which limits their oral bioavailability and therapeutic potential. In Chapter one, the ability of amorphous solid dispersions (ASDs), to improve the dissolution, pharmacokinetics ...
Gala, Urvi Hasmukhlal
core   +1 more source

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer

open access: yes, 2012
Yasser Rehman1, Jonathan E Rosenberg21Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA, USA; 2Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USAAbstract: Prostate cancer is
Rosenberg JE, Rehman Y
core  

Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer [PDF]

open access: yes
Background Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone coadministered with abiraterone can be immunosuppressive.
Tse, Gary   +9 more
core   +1 more source

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

open access: yesФармакоэкономика, 2019
Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC).
N. A. Avxentyev   +2 more
doaj   +1 more source

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.

open access: yes, 2023
PURPOSE: Adding ipatasertib to abiraterone and prednisone/prednisolone significantly improved radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN-loss tumours by immunohistochemistry ...
Bracarda, S   +29 more
core   +1 more source

Home - About - Disclaimer - Privacy